RecruitingNot ApplicableNCT07222410

Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital

Closed Loop Oxygen Control in COPD Patients Treated With Nasal High Flow in the Hospital

Sponsor

Fisher and Paykel Healthcare

Enrollment

70 participants

Start Date

Jan 7, 2026

Study Type

INTERVENTIONAL

Conditions

COPD

Summary

The trial aims to evaluate whether the Airvo 3 device in OptiO2 mode can maintain patients' SpO2 levels within the target range better than manual oxygen titration in hospitalized COPD patients with hypoxemia/respiratory distress.

Eligibility

Min Age: 22 Years

Inclusion Criteria6

Has cognitive ability to provide informed consent
Aged 22 years or older
Hospitalized with hypoxemia/respiratory distress
Diagnosis of COPD
Candidate for/currently prescribed nasal high flow (flow rate of at least 25 L/min) with supplemental oxygen, as assessed by the investigator
Expected duration of oxygen and nasal high flow therapy \>24 hours (not necessarily continuous)

Exclusion Criteria10

Receiving Non Invasive Ventilation (NIV) or indicated for NIV as per European Respiratory Society /American Thoracic Society guidelines
Hemodynamic instability (systolic blood pressure \<90mmHg or requirement for vasopressor or inotropic support)
Patient receiving end of life care
Nasal or facial conditions precluding use of nasal high flow
Pregnancy or breastfeeding
Cognitive impairment or impaired consciousness precluding informed consent
Unsuitable for adhesive finger pulse oximetry, as assessed by the investigator
Any other condition which, at the investigator's discretion, is believed to present a safety risk to the patient if included
The presence of any active comorbidities that affect the patient's condition importantly in the next 30 days, as assessed by the investigator
Has already participated in this clinical trial